Clearwater International advises on the sale of Ansel Group

Ansel-logo

Clearwater Advisor

Press Release

Clearwater International has advised Ansel Group, a specialist in personality disorder services, on its sale to London Stock Exchange-listed Cambian Group.

Established in 2008, Ansel works with people with complex mental health needs and operates 24 beds from its base in Nottingham. The business recently reported turnover of £3.5m in the year to March 2014.

Cambian Group is one of the UK’s largest providers of specialist behavioural health services to both adults and children. Established in 2004, the company has grown rapidly and currently employs 6,000 staff across its 250 facilities. Cambian works alongside 140 UK public authorities, offering services to almost 2,500 people. The business has performed strongly since listing on the LSE and has a market cap of over £385m.

The acquisition strengthens Cambian’s offering in the East Midlands, also allowing access to Ansel’s cutting edge Nottingham clinic. The deal also provides the opportunity for Ansel to extend its knowledge and client base.

Clearwater International’s Healthcare team, comprising partner Marcus Archer, director Ramesh Jassal and associate director Helen Lowe, advised Ansel on the sale.

“Personality disorder impacts 1.5 million people in the UK and continues to place high demands on health services and budgets. The demand for this type of care is high and has been met by Ansel in the East Midlands. Ansel’s clinically-led care offering has demonstrated that it can improve outcomes and lower the length of stay for patients. Ansel offers Cambian Group an opportunity to meet the unaddressed personality disorder market nationally, and we’re pleased to have assisted the group with its sale.”

Ramesh Jassal, Head of Healthcare at Clearwater International

“With Clearwater International’s considerable expertise in the healthcare sector and knowledge of the marketplace, they have found a strong partner for our business. The deal will enable Ansel to accelerate growth and offer its market-leading healthcare treatment to a greater number of patients. We look forward to working with Cambian over the coming months as we target the treatment of personality disorder on a much larger scale.”

Tom Burns, CEO at Ansel